
|Articles|December 1, 2004
Transaction is a surprise, but makes sense, analysts say
Although the news of Advanced Medical Optics Inc. (AMO) buying VISX caught many on Wall Street off guard, several analysts are saying the deal makes sense in retrospect.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
PainReform launches development plan for OcuRing-K, readies phase 2 trial
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
Phase 1 trial findings confirm safety and tolerability of Huons’ dry eye therapy
5















































.png)


